{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T15:45:43Z","timestamp":1772034343856,"version":"3.50.1"},"reference-count":239,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["SFB 1074"],"award-info":[{"award-number":["SFB 1074"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KU1917"],"award-info":[{"award-number":["01KU1917"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Cancer Biology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.semcancer.2021.03.034","type":"journal-article","created":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T19:15:31Z","timestamp":1619118931000},"page":"153-169","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":20,"special_numbering":"C","title":["Precision medicine in myeloid malignancies"],"prefix":"10.1016","volume":"84","author":[{"given":"J\u00f6rg","family":"Westermann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Bullinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.semcancer.2021.03.034_bib0005","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2017"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0010","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0015","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41568-019-0230-9","article-title":"The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML","volume":"20","author":"Vetrie","year":"2020","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0020","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1016\/j.cell.2008.10.048","article-title":"Hematopoietic stem cells reversibly switch from dormancy to self-renewal during homeostasis and repair","volume":"135","author":"Wilson","year":"2008","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0025","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1146\/annurev.cb.11.110195.000343","article-title":"The biology of hematopoietic stem cells","volume":"11","author":"Morrison","year":"1995","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0030","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.stem.2015.05.003","article-title":"Functionally distinct subsets of lineage-biased multipotent progenitors control blood production in normal and regenerative conditions","volume":"17","author":"Pietras","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0035","doi-asserted-by":"crossref","first-page":"7163","DOI":"10.1093\/nar\/gkz531","article-title":"DNA damage tolerance in stem cells, ageing, mutagenesis, disease and cancer therapy","volume":"47","author":"Pilzecker","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0040","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/mutage\/geh025","article-title":"Endogenous DNA damage in humans: a review of quantitative data","volume":"19","author":"De Bont","year":"2004","journal-title":"Mutagenesis"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0045","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: making it safe to play with knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol. Cell"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0050","doi-asserted-by":"crossref","first-page":"3465","DOI":"10.1073\/pnas.88.8.3465","article-title":"Exonucleolytic proofreading of leading and lagging strand DNA replication errors","volume":"88","author":"Roberts","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0055","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/nature05862","article-title":"Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age","volume":"447","author":"Rossi","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0060","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.stem.2010.06.014","article-title":"Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis","volume":"7","author":"Mohrin","year":"2010","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0065","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.celrep.2015.11.030","article-title":"Stem cell-specific mechanisms ensure genomic fidelity within HSCs and upon aging of HSCs","volume":"13","author":"Moehrle","year":"2015","journal-title":"Cell Rep."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0070","doi-asserted-by":"crossref","first-page":"3056","DOI":"10.1182\/blood-2007-05-087759","article-title":"A low level of reactive oxygen species selects for primitive hematopoietic stem cells that may reside in the low-oxygenic niche","volume":"110","author":"Jang","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0075","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/nature12631","article-title":"A canonical to non-canonical Wnt signalling switch in haematopoietic stem-cell ageing","volume":"503","author":"Florian","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0080","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/nature13619","article-title":"Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells","volume":"512","author":"Flach","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0085","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1158\/2159-8290.CD-18-1474","article-title":"Aging human hematopoietic stem cells manifest profound epigenetic reprogramming of enhancers that may predispose to leukemia","volume":"9","author":"Adelman","year":"2019","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0090","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.cell.2012.06.023","article-title":"The origin and evolution of mutations in acute myeloid leukemia","volume":"150","author":"Welch","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0095","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1056\/NEJMoa1409405","article-title":"Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence","volume":"371","author":"Genovese","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0100","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0105","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1056\/NEJMoa1701719","article-title":"Clonal hematopoiesis and atherosclerosis","volume":"377","author":"Jaiswal","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0110","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1182\/hematology.2019000045","article-title":"Inflammatory bone marrow microenvironment","volume":"2019","author":"Leimkuhler","year":"2019","journal-title":"Hematology Am. Soc. Hematol. Educ. Program"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0115","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1038\/ng.2413","article-title":"Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis","volume":"44","author":"Busque","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0120","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/nm.3733","article-title":"Age-related mutations associated with clonal hematopoietic expansion and malignancies","volume":"20","author":"Xie","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0125","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1038\/s41591-018-0081-z","article-title":"Somatic mutations precede acute myeloid leukemia years before diagnosis","volume":"24","author":"Desai","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0130","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1056\/NEJMoa0903840","article-title":"Recurring mutations found by sequencing an acute myeloid leukemia genome","volume":"361","author":"Mardis","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0135","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1111\/bjh.16360","article-title":"The power and potential of integrated diagnostics in acute myeloid leukaemia","volume":"188","author":"Haferlach","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0140","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1200\/JCO.2016.71.2208","article-title":"Genomics of acute myeloid leukemia diagnosis and pathways","volume":"35","author":"Bullinger","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0145","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1056\/NEJMoa031046","article-title":"Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia","volume":"350","author":"Bullinger","year":"2004","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ccr.2009.11.020","article-title":"DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia","volume":"17","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0155","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1056\/NEJMra1402513","article-title":"The key role of epigenetics in human disease prevention and mitigation","volume":"378","author":"Feinberg","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0160","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1056\/NEJMra1805035","article-title":"Epigenetic therapies for cancer","volume":"383","author":"Bates","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0165","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","article-title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0170","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0175","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0180","series-title":"Case of Hypertrophy of the Spleen and Liver, in Which Death Took Place from Suppuration of the Blood","author":"Bennett","year":"1845"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0185","first-page":"151","article-title":"Weisses blut","volume":"36","author":"Virchow","year":"1845","journal-title":"Frorieps Notizen"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0190","first-page":"1497","article-title":"A minute chromosome in human granulocytic leukemia","volume":"132","author":"Nowell","year":"1960","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0195","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0200","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1038\/300765a0","article-title":"A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia","volume":"300","author":"de Klein","year":"1982","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0205","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1038\/315758a0","article-title":"Structural organization of the bcr gene and its role in the Ph\u2019 translocation","volume":"315","author":"Heisterkamp","year":"1985","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0210","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1038\/306277a0","article-title":"Translocation of c-ab1 oncogene correlates with the presence of a Philadelphia chromosome in chronic myelocytic leukaemia","volume":"306","author":"Bartram","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0215","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/306239a0","article-title":"Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia","volume":"306","author":"Heisterkamp","year":"1983","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0220","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1126\/science.3460176","article-title":"The chronic myelogenous leukemia-specific P210 protein is the product of the bcr\/abl hybrid gene","volume":"233","author":"Ben-Neriah","year":"1986","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0225","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000140633","article-title":"BCR-ABL in chronic myelogenous leukemia\u2013how does it work?","volume":"119","author":"Goldman","year":"2008","journal-title":"Acta Haematol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0230","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/leu.2015.261","article-title":"Prognosis of long-term survival considering disease-specific death in patients with chronic myeloid leukemia","volume":"30","author":"Pfirrmann","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0235","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0240","doi-asserted-by":"crossref","first-page":"3074","DOI":"10.1182\/blood.V98.10.3074","article-title":"Chronic myeloid leukemia and interferon-alpha: a study of complete cytogenetic responders","volume":"98","author":"Bonifazi","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0245","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0250","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1056\/NEJMoa1609324","article-title":"Long-term outcomes of imatinib treatment for chronic myeloid leukemia","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0255","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1038\/leu.2017.253","article-title":"Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants","volume":"31","author":"Hehlmann","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0260","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/nrc2126","article-title":"Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia","volume":"7","author":"Weisberg","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0265","doi-asserted-by":"crossref","first-page":"7180","DOI":"10.1158\/1078-0432.CCR-17-0957","article-title":"Phase III clinical trial (RERISE study) results of efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia","volume":"23","author":"Kwak","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0270","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/bjh.16381","article-title":"Long-term data from a phase 3 study of radotinib versus imatinib in patients with newly diagnosed, chronic myeloid leukaemia in the chronic phase (RERISE)","volume":"189","author":"Do YR","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0275","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0280","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0285","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","article-title":"Asciminib in chronic myeloid leukemia after ABL kinase inhibitor failure","volume":"381","author":"Hughes","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0290","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0295","article-title":"Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase-3 studyof asciminib, a first-in-class STAMP inhibitor vs bosutinib in patients with chronic myeloid leukemia in chronic phase previously treated with \u2265 2 tyrosine kinase inhibitors","author":"Hochhaus","year":"2020","journal-title":"Am Soc of Hematol Ann Meeting 2020, LBA4, Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0300","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/leu.2016.5","article-title":"Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0305","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","article-title":"Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial","volume":"34","author":"Cortes","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0310","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1200\/JCO.2017.74.7162","article-title":"Bosutinib versus imatinib for newly diagnosed chronic myeloid leukemia: results from the randomized BFORE trial","volume":"36","author":"Cortes","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0315","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0320","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(18)30192-X","article-title":"Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial","volume":"19","author":"Saussele","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0325","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0330","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0335","doi-asserted-by":"crossref","first-page":"5565","DOI":"10.1182\/blood-2010-12-327437","article-title":"Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment","volume":"118","author":"Chu","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0340","doi-asserted-by":"crossref","first-page":"3657","DOI":"10.1182\/blood-2011-02-335497","article-title":"Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease","volume":"118","author":"Chomel","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0345","doi-asserted-by":"crossref","first-page":"2384","DOI":"10.1182\/blood-2016-07-728873","article-title":"Single-cell molecular analysis defines therapy response and immunophenotype of stem cell subpopulations in CML","volume":"129","author":"Warfvinge","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0350","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nm.4336","article-title":"Single-cell transcriptomics uncovers distinct molecular signatures of stem cells in chronic myeloid leukemia","volume":"23","author":"Giustacchini","year":"2017","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0355","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0360","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0365","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0370","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)71142-9","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0375","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0380","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0385","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3904\/kjim.2019.317","article-title":"Recent insights regarding the molecular basis of myeloproliferative neoplasms","volume":"35","author":"Jang","year":"2020","journal-title":"Korean J. Intern. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0390","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0395","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0400","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0405","article-title":"Driver mutation acquisition in utero and childhood followed by lifelong clonal evolution underlie myeloproliferative neoplasms","author":"Williams","year":"2020","journal-title":"Am Soc Hematol Ann Meeting, LBA1, Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0410","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms","volume":"369","author":"Klampfl","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0415","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0420","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1182\/blood-2017-09-806356","article-title":"Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage","volume":"131","author":"Li","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0425","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/leu.2015.277","article-title":"Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms","volume":"30","author":"Pietra","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0430","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41467-019-13892-x","article-title":"Single-cell analysis based dissection of clonality in myelofibrosis","volume":"11","author":"Mylonas","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.semcancer.2021.03.034_bib0435","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.3324\/haematol.2019.243121","article-title":"Bone marrow niche dysregulation in myeloproliferative neoplasms","volume":"105","author":"Curto-Garcia","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0440","doi-asserted-by":"crossref","first-page":"5630","DOI":"10.1200\/JCO.2007.12.6896","article-title":"Familial chronic myeloproliferative disorders: clinical phenotype and evidence of disease anticipation","volume":"25","author":"Rumi","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0445","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2016-04-711150","article-title":"LNK mutations in familial myeloproliferative neoplasms","volume":"128","author":"Rumi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0450","doi-asserted-by":"crossref","first-page":"2266","DOI":"10.1182\/blood-2016-04-711283","article-title":"Coexistence of gain-of-function JAK2 germ line mutations with JAK2V617F in polycythemia vera","volume":"128","author":"Lanikova","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0455","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1038\/s41375-018-0077-1","article-title":"Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet","volume":"32","author":"Barbui","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0460","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1110557","article-title":"A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis","volume":"366","author":"Verstovsek","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0465","doi-asserted-by":"crossref","first-page":"5128","DOI":"10.1182\/blood-2012-07-444067","article-title":"Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia (IPSET-thrombosis)","volume":"120","author":"Barbui","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0470","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1056\/NEJMoa1110556","article-title":"JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis","volume":"366","author":"Harrison","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0475","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1186\/s13045-017-0417-z","article-title":"Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial","volume":"10","author":"Verstovsek","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0480","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13045-018-0585-5","article-title":"Long-term effects of ruxolitinib versus best available therapy on bone marrow fibrosis in patients with myelofibrosis","volume":"11","author":"Kvasnicka","year":"2018","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0485","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1001\/jamaoncol.2015.1590","article-title":"Safety and efficacy of Fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial","volume":"1","author":"Pardanani","year":"2015","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0490","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1056\/NEJMoa1409002","article-title":"Ruxolitinib versus standard therapy for the treatment of polycythemia vera","volume":"372","author":"Vannucchi","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0495","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S1470-2045(16)30558-7","article-title":"Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study","volume":"18","author":"Passamonti","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0500","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/bjh.14382","article-title":"The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF)","volume":"176","author":"Mesa","year":"2017","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0505","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3324\/haematol.2016.143644","article-title":"Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial","volume":"101","author":"Verstovsek","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0510","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1002\/ajh.25688","article-title":"Chronic neutrophilic leukemia: 2020 update on diagnosis, molecular genetics, prognosis, and management","volume":"95","author":"Szuber","year":"2020","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0515","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1056\/NEJMoa1214514","article-title":"Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML","volume":"368","author":"Maxson","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0520","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2013.122","article-title":"CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia","volume":"27","author":"Pardanani","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0525","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jaci.2012.02.019","article-title":"Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes","volume":"130","author":"Valent","year":"2012","journal-title":"J. Allergy Clin. Immunol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0530","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0535","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1073\/pnas.0932698100","article-title":"Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome","volume":"100","author":"Griffin","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0540","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1182\/blood-2016-10-695973","article-title":"Myeloid neoplasms with eosinophilia","volume":"129","author":"Reiter","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0545","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/ajh.25617","article-title":"World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management","volume":"94","author":"Shomali","year":"2019","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0550","first-page":"1176","article-title":"Novel treatment strategies for myeloproliferative neoplasms","volume":"60","author":"Bose","year":"2019","journal-title":"Rinsho Ketsueki"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0555","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3324\/haematol.2016.146563","article-title":"Advanced systemic mastocytosis: from molecular and genetic progress to clinical practice","volume":"101","author":"Ustun","year":"2016","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0560","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1056\/NEJMoa1513098","article-title":"Efficacy and safety of midostaurin in advanced systemic mastocytosis","volume":"374","author":"Gotlib","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0565","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/nrc.2016.112","article-title":"The genetics of myelodysplastic syndrome: from clonal haematopoiesis to secondary leukaemia","volume":"17","author":"Sperling","year":"2017","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0570","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic syndromes","volume":"383","author":"Cazzola","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0575","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/leu.2013.336","article-title":"Landscape of genetic lesions in 944 patients with myelodysplastic syndromes","volume":"28","author":"Haferlach","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0580","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1182\/blood-2018-10-844662","article-title":"Genetic predisposition to MDS: clinical features and clonal evolution","volume":"133","author":"Kennedy","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0585","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ccr.2014.03.036","article-title":"Myelodysplastic syndromes are propagated by rare and distinct human cancer stem cells in vivo","volume":"25","author":"Woll","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0590","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/nature05610","article-title":"Patterns of somatic mutation in human cancer genomes","volume":"446","author":"Greenman","year":"2007","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0595","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"Alexandrov","year":"2013","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0600","doi-asserted-by":"crossref","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0605","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1182\/blood-2017-01-763425","article-title":"Clinical significance of somatic mutation in unexplained blood cytopenia","volume":"129","author":"Malcovati","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0610","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1182\/blood-2015-08-667063","article-title":"MDS-associated somatic mutations and clonal hematopoiesis are common in idiopathic cytopenias of undetermined significance","volume":"126","author":"Kwok","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0615","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1200\/JCO.2016.71.0806","article-title":"Clinical implications of genetic mutations in myelodysplastic syndrome","volume":"35","author":"Kennedy","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0620","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0625","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1182\/blood-2018-10-844639","article-title":"The mesenchymal niche in MDS","volume":"133","author":"Pronk","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0630","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3109\/10428194.2012.718341","article-title":"Rationale for the clinical application of flow cytometry in patients with myelodysplastic syndromes: position paper of an International Consortium and the European LeukemiaNet Working Group","volume":"54","author":"van de Loosdrecht","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0635","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/blood-2015-03-631747","article-title":"Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes","volume":"126","author":"Steensma","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0640","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1016\/S2352-3026(19)30211-X","article-title":"Assessing clonal haematopoiesis: clinical burdens and benefits of diagnosing myelodysplastic syndrome precursor states","volume":"7","author":"Gondek","year":"2020","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0645","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0650","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","author":"Greenberg","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0655","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1056\/NEJMoa1013343","article-title":"Clinical effect of point mutations in myelodysplastic syndromes","volume":"364","author":"Bejar","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0660","doi-asserted-by":"crossref","first-page":"3376","DOI":"10.1200\/JCO.2011.40.7379","article-title":"Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes","volume":"30","author":"Bejar","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0665","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1182\/blood-2016-02-700054","article-title":"Time-dependent changes in mortality and transformation risk in MDS","volume":"128","author":"Pfeilstocker","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0670","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","article-title":"Treatment of MDS","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0675","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/j.ccr.2014.08.001","article-title":"Role of casein kinase 1A1 in the biology and targeted therapy of del(5q) MDS","volume":"26","author":"Schneider","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0680","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1038\/nature14610","article-title":"Lenalidomide induces ubiquitination and degradation of CK1alpha in del(5q) MDS","volume":"523","author":"Kronke","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0685","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood-2011-01-330126","article-title":"A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with del5q","volume":"118","author":"Fenaux","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0690","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1038\/leu.2011.268","article-title":"Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide","volume":"26","author":"Giagounidis","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0695","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/ejh.12380","article-title":"Outcomes in RBC transfusion-dependent patients with Low-\/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study","volume":"93","author":"Giagounidis","year":"2014","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0700","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.3324\/haematol.2009.011528","article-title":"Clonal heterogeneity in the 5q- syndrome: p53 expressing progenitors prevail during lenalidomide treatment and expand at disease progression","volume":"94","author":"Jadersten","year":"2009","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0705","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1038\/leu.2016.111","article-title":"Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS)","volume":"30","author":"Mossner","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0710","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/leu.2015.304","article-title":"Impact of TP53 mutation variant allele frequency on phenotype and outcomes in myelodysplastic syndromes","volume":"30","author":"Sallman","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0715","doi-asserted-by":"crossref","first-page":"498","DOI":"10.3324\/haematol.2016.152025","article-title":"Progression in patients with low- and intermediate-1-risk del(5q) myelodysplastic syndromes is predicted by a limited subset of mutations","volume":"102","author":"Scharenberg","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0720","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.2015.66.0118","article-title":"Randomized phase III study of lenalidomide versus placebo in RBC transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes and ineligible for or refractory to erythropoiesis-stimulating agents","volume":"34","author":"Santini","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0725","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1038\/leu.2015.296","article-title":"Lenalidomide with or without erythropoietin in transfusion-dependent erythropoiesis-stimulating agent-refractory lower-risk MDS without 5q deletion","volume":"30","author":"Toma","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0730","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1182\/blood-2008-02-139824","article-title":"Inhibition of the TGF-beta receptor I kinase promotes hematopoiesis in MDS","volume":"112","author":"Zhou","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0735","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1158\/0008-5472.CAN-10-2933","article-title":"Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase","volume":"71","author":"Zhou","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0740","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1016\/S1470-2045(17)30615-0","article-title":"Luspatercept for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes (PACE-MDS): a multicentre, open-label phase 2 dose-finding study with long-term extension study","volume":"18","author":"Platzbecker","year":"2017","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0745","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0750","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"Dohner","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0755","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00277-017-3150-3","article-title":"Epidemiological, genetic, and clinical characterization by age of newly diagnosed acute myeloid leukemia based on an academic population-based registry study (AMLSG BiO)","volume":"96","author":"Nagel","year":"2017","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0760","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.beha.2017.10.002","article-title":"Familial myelodysplastic syndrome\/acute myeloid leukemia","volume":"30","author":"Churpek","year":"2017","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0765","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.siny.2012.02.010","article-title":"Biology and management of transient abnormal myelopoiesis (TAM) in children with Down syndrome","volume":"17","author":"Roy","year":"2012","journal-title":"Semin. Fetal Neonatal Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0770","first-page":"608","article-title":"Distinctive demography, biology, and outcome of acute myeloid leukemia and myelodysplastic syndrome in children with Down syndrome: children\u2019s cancer group studies 2861 and 2891","volume":"91","author":"Lange","year":"1998","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0775","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.1200\/JCO.2005.05.010","article-title":"Genetics of myeloid malignancies: pathogenetic and clinical implications","volume":"23","author":"Frohling","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0780","doi-asserted-by":"crossref","first-page":"5593","DOI":"10.1182\/blood-2011-03-343988","article-title":"Gene mutation patterns and their prognostic impact in a cohort of 1185 patients with acute myeloid leukemia","volume":"118","author":"Shen","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0785","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nature07485","article-title":"DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome","volume":"456","author":"Ley","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0790","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1038\/nature10738","article-title":"Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0795","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1056\/NEJMoa1106968","article-title":"Clonal architecture of secondary acute myeloid leukemia","volume":"366","author":"Walter","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0800","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s11912-020-0885-0","article-title":"Acute myeloid leukaemia in its niche: the bone marrow microenvironment in acute myeloid leukaemia","volume":"22","author":"Ladikou","year":"2020","journal-title":"Curr. Oncol. Rep."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0805","doi-asserted-by":"crossref","first-page":"987","DOI":"10.3324\/haematol.2018.214379","article-title":"Mesenchymal stromal cells confer chemoresistance to myeloid leukemia blasts through Side Population functionality and ABC transporter activation","volume":"105","author":"Boutin","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0810","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1056\/NEJMoa1301689","article-title":"Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia","volume":"368","author":"Ley","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0815","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute myeloid leukemia","volume":"373","author":"Dohner","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0820","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic classification and prognosis in acute myeloid leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0825","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1200\/JCO.19.00416","article-title":"Chromosomal abnormalities and prognosis in NPM1-mutated acute myeloid leukemia: a pooled analysis of individual patient data from nine international cohorts","volume":"37","author":"Angenendt","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0830","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1716863","article-title":"Molecular minimal residual disease in acute myeloid leukemia","volume":"378","author":"Jongen-Lavrencic","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0835","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0840","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1182\/blood.2019001425","article-title":"Measurable residual disease monitoring in acute myeloid leukemia with t(8;21)(q22;q22.1): results from the AML Study Group","volume":"134","author":"Rucker","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0845","doi-asserted-by":"crossref","first-page":"2709","DOI":"10.1200\/JCO.2011.35.0371","article-title":"Monitoring of minimal residual disease in NPM1-mutated acute myeloid leukemia: a study from the German-Austrian acute myeloid leukemia study group","volume":"29","author":"Kronke","year":"2011","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0850","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s00277-018-3480-9","article-title":"Classifying AML patients with inv(16) into high-risk and low-risk relapsed patients based on peritransplantation minimal residual disease determined by CBFbeta\/MYH11 gene expression","volume":"98","author":"Xiaosu","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0855","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1200\/JCO.2017.77.6757","article-title":"Clearance of somatic mutations at remission and the risk of relapse in acute myeloid leukemia","volume":"36","author":"Morita","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0860","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.0954-6820.1957.tb00124.x","article-title":"Acute promyelocytic leukemia","volume":"159","author":"Hillestad","year":"1957","journal-title":"Acta Med. Scand."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0865","doi-asserted-by":"crossref","DOI":"10.4084\/mjhid.2011.067","article-title":"History of acute promyelocytic leukemia: a tale of endless revolution","volume":"3","author":"Lo-Coco","year":"2011","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0870","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1182\/blood-2009-07-233387","article-title":"Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience","volume":"115","author":"Ades","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0875","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1056\/NEJMoa1300874","article-title":"Retinoic acid and arsenic trioxide for acute promyelocytic leukemia","volume":"369","author":"Lo-Coco","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0880","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1038\/sj.leu.2401843","article-title":"Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group","volume":"14","author":"Lengfelder","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0885","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/S0140-6736(77)91415-5","article-title":"15\/17 translocation, a consistent chromosomal change in acute promyelocytic leukaemia","volume":"1","author":"Rowley","year":"1977","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0890","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0092-8674(93)80044-F","article-title":"The acute promyelocytic leukemia-specific PML-RAR alpha fusion protein inhibits differentiation and promotes survival of myeloid precursor cells","volume":"74","author":"Grignani","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0895","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood.V72.2.567.567","article-title":"Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia","volume":"72","author":"Huang","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0900","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1084\/jem.189.7.1043","article-title":"Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia","volume":"189","author":"Lallemand-Breitenbach","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0905","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/nrc2943","article-title":"Acute promyelocytic leukaemia: novel insights into the mechanisms of cure","volume":"10","author":"de The","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.semcancer.2021.03.034_bib0910","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1038\/s41375-020-0758-4","article-title":"Outcome of older (&\/=70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study","volume":"34","author":"Kayser","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0915","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1038\/sj.leu.2401635","article-title":"Expression of Flt3-ligand by the endothelial cell","volume":"14","author":"Solanilla","year":"2000","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0920","first-page":"1911","article-title":"Internal tandem duplication of the flt3 gene found in acute myeloid leukemia","volume":"10","author":"Nakao","year":"1996","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0925","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18061115","article-title":"The cytokine Flt3-ligand in normal and malignant hematopoiesis","volume":"18","author":"Tsapogas","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0930","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","article-title":"Targeting FLT3 mutations in AML: review of current knowledge and evidence","volume":"33","author":"Daver","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0935","doi-asserted-by":"crossref","first-page":"4339","DOI":"10.1200\/JCO.2010.28.9678","article-title":"Phase IIB trial of oral Midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3","volume":"28","author":"Fischer","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0940","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1056\/NEJMoa1614359","article-title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation","volume":"377","author":"Stone","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0945","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1056\/NEJMoa1902688","article-title":"Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML","volume":"381","author":"Perl","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0950","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1016\/S1470-2045(19)30150-0","article-title":"Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"20","author":"Cortes","year":"2019","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0955","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/nm.4484","article-title":"Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells","volume":"24","author":"Mathew","year":"2018","journal-title":"Nat. Med."},{"issue":"Suppl. 1","key":"10.1016\/j.semcancer.2021.03.034_bib0960","article-title":"Radius: a phase-2 randomized trial investigating standard of care +\/- midostaurin after allogeneic stem cell transplant in Flt3-ITD-mutated AML","volume":"132","author":"Maziarz","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0965","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1200\/JCO.19.03345","article-title":"Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)","volume":"38","author":"Burchert","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0970","doi-asserted-by":"crossref","first-page":"e218","DOI":"10.1038\/bcj.2014.39","article-title":"Distribution and levels of cell surface expression of CD33 and CD123 in acute myeloid leukemia","volume":"4","author":"Ehninger","year":"2014","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0975","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","article-title":"Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin","volume":"17","author":"Ricart","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0980","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/S1470-2045(14)70281-5","article-title":"Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials","volume":"15","author":"Hills","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib0985","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1016\/S0140-6736(12)60485-1","article-title":"Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study","volume":"379","author":"Castaigne","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0990","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.03.034_bib0995","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1200\/JCO.19.01406","article-title":"Gemtuzumab ozogamicin in NPM1-mutated acute myeloid leukemia: early results from the prospective randomized AMLSG 09-09 phase III study","volume":"38","author":"Schlenk","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1000","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00280-017-3484-5","article-title":"Persistent cytarabine and daunorubicin exposure after administration of novel liposomal formulation CPX-351: population pharmacokinetic assessment","volume":"81","author":"Nikanjam","year":"2018","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1005","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.leukres.2010.01.015","article-title":"Leukemia-selective uptake and cytotoxicity of CPX-351, a synergistic fixed-ratio cytarabine:daunorubicin formulation, in bone marrow xenografts","volume":"34","author":"Lim","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1010","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/j.exphem.2011.04.001","article-title":"Liposomal encapsulation of a synergistic molar ratio of cytarabine and daunorubicin enhances selective toxicity for acute myeloid leukemia progenitors as compared to analogous normal hematopoietic cells","volume":"39","author":"Kim","year":"2011","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1015","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1200\/JCO.2017.77.6112","article-title":"CPX-351 (cytarabine and daunorubicin) liposome for injection versus conventional cytarabine plus daunorubicin in older patients with newly diagnosed secondary acute myeloid leukemia","volume":"36","author":"Lancet","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1020","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1084\/jem.20092506","article-title":"Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations","volume":"207","author":"Gross","year":"2010","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1025","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib1030","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1126\/science.1164382","article-title":"An integrated genomic analysis of human glioblastoma multiforme","volume":"321","author":"Parsons","year":"2008","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2021.03.034_bib1035","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1182\/blood-2018-08-869008","article-title":"Molecular remission and response patterns in patients with mutant-IDH2 acute myeloid leukemia treated with enasidenib","volume":"133","author":"Stein","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib1040","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1038\/s41375-019-0472-2","article-title":"Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia","volume":"33","author":"Pollyea","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib1045","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1050","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","author":"Roboz","year":"2020","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.semcancer.2021.03.034_bib1055","volume":"134","author":"Di Nardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib1060","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1200\/JCO.20.01632","article-title":"Mutant isocitrate dehydrogenase 1 inhibitor ivosidenib in combination with azacitidine for newly diagnosed acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1065","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/2159-8290.CD-18-0877","article-title":"Isoform switching as a mechanism of acquired resistance to mutant isocitrate dehydrogenase inhibition","volume":"8","author":"Harding","year":"2018","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1070","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1038\/s41586-018-0251-7","article-title":"Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations","volume":"559","author":"Intlekofer","year":"2018","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.03.034_bib1075","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","author":"Konopleva","year":"2006","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2021.03.034_bib1080","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.cell.2012.08.038","article-title":"Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML","volume":"151","author":"Vo","year":"2012","journal-title":"Cell"},{"key":"10.1016\/j.semcancer.2021.03.034_bib1085","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1158\/2159-8290.CD-13-0609","article-title":"Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia","volume":"4","author":"Pan","year":"2014","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1090","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1038\/s41418-019-0391-9","article-title":"BH3 profiling discriminates on-target small molecule BH3 mimetics from putative mimetics","volume":"27","author":"Villalobos-Ortiz","year":"2020","journal-title":"Cell Death Differ."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1095","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1100","doi-asserted-by":"crossref","first-page":"2144","DOI":"10.3324\/haematol.2018.208603","article-title":"Sequential and combination treatments with novel agents in chronic lymphocytic leukemia","volume":"104","author":"Furstenau","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.semcancer.2021.03.034_bib1105","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","author":"Konopleva","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1110","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1200\/JCO.18.01600","article-title":"Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: results from a phase Ib\/II study","volume":"37","author":"Wei","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1115","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib1120","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1125","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1182\/blood.2020004856","article-title":"Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial","volume":"135","author":"Wei","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib1130","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1135","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s12943-016-0509-3","article-title":"Hedgehog signaling: modulation of cancer properies and tumor mircroenvironment","volume":"15","author":"Hanna","year":"2016","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.semcancer.2021.03.034_bib1140","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1182\/blood-2011-10-383752","article-title":"Targeting hedgehog in hematologic malignancy","volume":"119","author":"Irvine","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.semcancer.2021.03.034_bib1145","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1158\/1078-0432.CCR-14-1436","article-title":"Evolutionarily conserved signaling pathways: acting in the shadows of acute myelogenous leukemia\u2019s genetic diversity","volume":"21","author":"Heidel","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1150","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1111\/cas.13019","article-title":"Small-molecule Hedgehog inhibitor attenuates the leukemia-initiation potential of acute myeloid leukemia cells","volume":"107","author":"Fukushima","year":"2016","journal-title":"Cancer Sci."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1155","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41375-018-0312-9","article-title":"Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome","volume":"33","author":"Cortes","year":"2019","journal-title":"Leukemia"},{"key":"10.1016\/j.semcancer.2021.03.034_bib1160","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1056\/NEJMoa2024534","article-title":"Genome sequencing as an alternative to cytogenetic analysis in myeloid cancers","volume":"384","author":"Duncavage","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1165","doi-asserted-by":"crossref","first-page":"76","DOI":"10.3389\/fgene.2020.00076","article-title":"Nanopore Sequencing in blood diseases: a wide range of opportunities","volume":"11","author":"Minervini","year":"2020","journal-title":"Front. Genet."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1170","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1126\/science.342.6165.1432","article-title":"Breakthrough of the year 2013. Cancer immunotherapy","volume":"342","author":"Couzin-Frankel","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.semcancer.2021.03.034_bib1175","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/nature13988","article-title":"Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens","volume":"515","author":"Gubin","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.semcancer.2021.03.034_bib1180","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100654","article-title":"BITES and CARS and checkpoints, oh my! Updates regarding immunotherapy for myeloid malignancies from the 2018 annual ASH meeting","author":"Przespolewski","year":"2020","journal-title":"Blood Rev."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1185","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1172\/JCI129204","article-title":"Immune escape and immunotherapy of acute myeloid leukemia","volume":"130","author":"Vago","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.semcancer.2021.03.034_bib1190","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A potent and selective small-molecule degrader of STAT3 achieves complete tumor regression in vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.semcancer.2021.03.034_bib1195","doi-asserted-by":"crossref","first-page":"4744","DOI":"10.1158\/0008-5472.CAN-19-1236","article-title":"Targeting BCR-ABL1 in chronic myeloid leukemia by PROTAC-mediated targeted protein degradation","volume":"79","author":"Burslem","year":"2019","journal-title":"Cancer Res."}],"container-title":["Seminars in Cancer Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X21000845?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1044579X21000845?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T23:54:50Z","timestamp":1760918090000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1044579X21000845"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":239,"alternative-id":["S1044579X21000845"],"URL":"https:\/\/doi.org\/10.1016\/j.semcancer.2021.03.034","relation":{},"ISSN":["1044-579X"],"issn-type":[{"value":"1044-579X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision medicine in myeloid malignancies","name":"articletitle","label":"Article Title"},{"value":"Seminars in Cancer Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semcancer.2021.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}